These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24340436)

  • 1. [The immune system in atherosclerosis. Immunomodulatory or anti-inflammatory treatment that is effective against atherosclerosis and its complications are needed to ensure the hypothesis].
    Frostegård J
    Lakartidningen; 2013 Oct 23-29; 110(43-44):1931-4. PubMed ID: 24340436
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiometabolic risk-factor management.
    Ker J
    Cardiovasc J Afr; 2008; 19(4):222-4. PubMed ID: 18776972
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?
    Heeneman S; Donners MM; Bai L; Daemen MJ
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):345-64. PubMed ID: 17338677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-inflammatory mechanism of statins in atherosclerosis management].
    Zhao SP
    Zhonghua Yi Xue Za Zhi; 2005 Oct; 85(40):2818-20. PubMed ID: 16324336
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune mechanisms involved in cardiovascular complications of chronic kidney disease.
    Stinghen AE; Bucharles S; Riella MC; Pecoits-Filho R
    Blood Purif; 2010; 29(2):114-20. PubMed ID: 20093815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for lipids.
    Treat Guidel Med Lett; 2011 Mar; 9(103):13-20. PubMed ID: 21350395
    [No Abstract]   [Full Text] [Related]  

  • 7. Statins and other agents for vascular inflammation.
    Owens CD
    J Vasc Surg; 2012 Dec; 56(6):1799-806. PubMed ID: 23017371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study.
    Targher G
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1251-2. PubMed ID: 21593456
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies.
    Klingenberg R; Hansson GK
    Eur Heart J; 2009 Dec; 30(23):2838-44. PubMed ID: 19880848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting inflammation in cardiovascular diseases. still a neglected field?
    Gómez-Guerrero C; Mallavia B; Egido J
    Cardiovasc Ther; 2012 Aug; 30(4):e189-97. PubMed ID: 21884009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic inflammation increases the risk of cardiovascular disease in patients with rheumatoid arthritis].
    Troelsen LN; Jacobsen S
    Ugeskr Laeger; 2006 Sep; 168(39):3304-8. PubMed ID: 17032593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
    Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
    [No Abstract]   [Full Text] [Related]  

  • 15. Statins and autoimmune diseases.
    Riboldi P; Gerosa M; Meroni PL
    Lupus; 2005; 14(9):765-8. PubMed ID: 16218484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
    Olsson AG
    Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
    [No Abstract]   [Full Text] [Related]  

  • 17. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the preventive effect of different drugs depend on location of the atherosclerotic process?
    Poredos P; Jezovnik MK
    Int Angiol; 2008 Aug; 27(4):274-80. PubMed ID: 18677288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-atherosclerotic and anti-inflammatory effects of statin on cardiovascular disease and their mechanisms].
    Ishibashi T
    Nihon Rinsho; 2011 Jan; 69(1):79-84. PubMed ID: 21226265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of statins on perioperative cardiovascular outcome.
    Dunkelgrun M; Schouten O; Feringa HH; Vidakovic R; Poldermans D
    Curr Opin Anaesthesiol; 2006 Aug; 19(4):418-22. PubMed ID: 16829724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.